Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.

Slides:



Advertisements
Similar presentations
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.
Advertisements

Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.
CLINICAL CHARACTERISTICS AND OUTCOMES FOR BENIGN AND MALIGNANT SOLITARY FIBROUS TUMOR / HEMANGIOPERICYTOMA (SFT/HPC) – A SINGLE CENTER EXPERIENCE Nicholas.
Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Departments - Surgery - Gerontology and Geriatrics Department of SurgeryDepartment of Gerontology & Geriatrics Prof. dr. C.J.H. van de VeldeProf. dr. R.G.J.
Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.
AATS Postgraduate Course April 26, 2015 N2 - Current Evidence: Is There Role for Surgery? Is There a Role for Postop Radiation for Surprise N2? Linda W.
Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;
Lymphadenectomy in Epithelial Ovarian Cancer
Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.
Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
中山大学肿瘤防治中心 SUN YAT-SEN UNIVERSITY CANCER CENTER Trends in the survival of patients with nasopharyngeal carcinoma in Sihui city, Guangdong province,
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
First author: Roman Adina Co-author: Andone Sebastian
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.
Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,
on behalf of the ACOSOG Z4032 Investigators
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.
Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
Malignancy Grade and Histologic Subtype of Primary Retroperitoneal Sarcoma (RPS) are Predictive of Pattern of Recurrence: a Large Retrospective Study from.
The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,
14 th Annual Meeting of the Connective Tissue Oncology Society November 13-15, 2008, London, UK Oliver Zivanovic, Mario M. Leitao, Alexia Iasonos, Lindsay.
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Nabhan C et al. Proc ICML 2013;Abstract 102.
Patterns of Care and Prognosis of Retroperitoneal Sarcomas in the Primary and Advanced Settings A Large Multicentric Retrospective Analysis from the French.
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Association of Family History with Cancer Recurrence and Survival in Patients with Gastric Cancer Journal of Clinical Oncology : R2 Hwang.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,
COMPARING DISEASE OUTCOME OF WOMEN WITH HORMONE RECEPTOR NEGATIVE/HER2 POSITIVE (HR-/HER2+) OR TRIPLE NEGATIVE (TN) METASTATIC BREAST CANCER (MBC) RECEIVING.
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
Prognostic significance of tumor subtypes in male breast cancer:
R. Michelle Sarin, MD Mentor: Jeffrey Fowler, MD
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Prognosis of younger patients in non-small cell lung cancer
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.
MJ O’Connell for the ACCENT Collaborative Group
Published online September 20, 2017 by JAMA Surgery
Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
高雄榮民總醫院耳鼻喉頭頸部 林陞樵 林曜祥 康柏皇 張庭碩
GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR
Surgical resection of metachronous liver metastases
Presentation transcript:

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)

Disclosure None Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Disclosure None

Background Torino, Italy Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Background Torino, Italy

LCNC Rare tumor (2% to 3% all resected primary lung cancers) Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative diagnosis is often impossible Clinical behavior and prognosis similar to SCLC Surgery alone is insufficient to treat LCNC, even in early Stages

Biologically related to Neuroendocrine Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Biologically related to Neuroendocrine tumors, but still considered a variant of LCCs, and therefore, accordingly treated

Garcia-Yuste et al. 2000 22 21 % 33 % 59 % Takey et al. 2003 87 57 % Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Author Year N° pts 5-y OS 5-y OS Stage I Recurrence % Garcia-Yuste et al. 2000 22 21 % 33 % 59 % Takey et al. 2003 87 57 % 67 % 40 % Battafarano et al. 2004 45 30 % 49 % Paci et al. 48 27 % NA Rossi et al. 2005 83 65 % Veronesi et al. 2006 144 42 % 52 % Sarkaria et al. 2011 100 58 % 38 %

LCNC Due to its rarity and the lack of RCT, the optimal treatment Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery LCNC Due to its rarity and the lack of RCT, the optimal treatment is still debated Few clinical papers evaluated the role of induction/adjuvant CT

3 years ago… The ESTS Lung NETs-WG was created with the aim to: Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery 3 years ago… The ESTS Lung NETs-WG was created with the aim to: create a group of physicians worldwide expert in NETs develop scientific knowledge on such rare neoplasms

2014: 14 Centres 2054 patients Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery 2014: 14 Centres 2054 patients

Aim of the study Torino, Italy Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Aim of the study Torino, Italy

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Aim of the study To evaluate the possible adjuvant CT effect on LCNC survival To assess clinicopathologic prognostic factors in a surgically-based population of patient with LCNC

Methods Torino, Italy Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Methods Torino, Italy

Study Flow-Chart 400 patients median FU: 38 months Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery 460 patients with LCNC surgically treated between 1992-2014 in 14 Centers 28 patients with missing information on vital status   432 Patients Study Flow-Chart 32 patients with missing information concerning adjuvant chemotherapy   400 patients median FU: 38 months % FU completeness: 94%

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery LCNC diagnosis All the histological samples were reviewed by local NETs expert Pathologists LCNC definitive diagnosis was made according to: 2004 WHO Lung Tumors Classification criteria Travis’ histological guidelines for NETs diagnosis

NET morphological/immunohistochemical Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery NET morphological/immunohistochemical characteristics: Neuroendocrine morphology (organoid nesting, palisading rosettes and trabeculae High mitotic rate (11 or more) Abundant necrosis Large cell size Low nuclear/citoplasm ratio Tumor cells positive for neuroendocrine markers: Synaptophysisn Chromogranin A CD56 Chromogranin A Synaptophysisn

Retrospective multicentre study Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Demographics Age Gender Smoking habit Clinical variables Previous malignancy Tumor site PS (ECOG) Tumor-related variables Stage (TNM 7° edition) Retrospective multicentre study Outcome measure : overall survival (OS) Cox proportion hazard model with shared frailty (for center heterogeneity) Treatment variables Type of surgical resection Completness of resection Use of chemotherapy

Results Torino, Italy Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Results Torino, Italy

400 pts No. % Age (median – IQR-) 66 (58-72) Gender (male) 252 63 Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery No. % Age (median – IQR-) 66 (58-72) Gender (male) 252 63 Smokers (current/former) 99 25 Previous malignancy pTNM I 185 48 II 110 29 III 76 20 IV 12 3 Induction therapy 53 (44 CT; 9 RT) 13 Adjuvant CT 146 37 Adjuvant RT 38 10 400 pts

Type of surgery R0 resection: 360 cases (97%) Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Type of surgery R0 resection: 360 cases (97%)

(69 in the adjuvant CT group) Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Median FU: 38 months FU completeness: 94% 213 patients died (69 in the adjuvant CT group)

Overall survival Median OS: 43 months 3-y surv rate: 54 % Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Overall survival 0.00 0.25 0.50 0.75 1.00 400 292 202 149 110 94 70 54 35 25 22 At risk: 12 24 36 48 60 72 84 96 108 120 Months Median OS: 43 months 3-y surv rate: 54 % 5-y surv rate: 45 %

adjuvant CT administration Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery OS according to adjuvant CT administration 0.00 0.25 0.50 0.75 1.00 146 110 76 57 42 35 28 21 13 6 5 Yes 254 182 126 92 68 59 33 22 19 17 No At risk: 12 24 36 48 60 72 84 96 108 120 Months A slight improvement in OS was observed in those who received adjuvant CT (HR 0.82; 95%CI: 0.62-1.09, P=0.17)

Multivariate analysis Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Multivariate analysis Variable HR (95%CI) P Adjuvant Chemoterapy YES vs NO (adjusted for the below factors) 0.74 (0.53 to 1.02) 0.06 Age (per 1 year increase) 1.03 (1.01 to 1.04) 0.001 Male gender 1.18 (0.87 to 1.59) 0.28 Previous Malignancy 1.01 (0.73 to 1.39) 0.94 ECOG PS>=2 1.62 (1.21 to 2.16) Vascular Invasion 1.29 (0.95 to 1.77) 0.11 pTNM II vs I 1.4 (0.98 to 2.01) III/IV vs I 2.57 (1.76 to 3.76) <0.001 Year of Surgery 2000-2007 vs 1992-1999 0.74 (0.49 to 1.12) 0.15 2008-2014 vs 1992-1999 0.61 (0.38 to 0.95) 0.03 An evidence of a higher OS in adjuvant CT was observed

The subgroup analysis did not show Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Subgroup Analysis for the effect of administration of adjuvant Chemotherapy Variable HR (95%CI) P-Interaction Overall 0.74 (0.53 to 1.02) Age 0.64 <65 0.69 (0.43 to 1.1) >=65 0.8 (0.52 to 1.21) Gender 0.6 Female 0.83 (0.49 to 1.42) Male 0.7 (0.48 to 1.02) Previous Malignancy 0.34 No 0.8 (0.56 to 1.14) Yes 0.56 (0.29 to 1.08) Vascular Invasion 0.25 0.65 (0.4 to 1.06) 0.96 (0.6 to 1.56) pTNM 0.99 I 0.71 (0.36 to 1.41) II 0.75 (0.44 to 1.28) III-IV 0.76 (0.44 to 1.3) The subgroup analysis did not show any subset of patients that significantly benefited from adjuvant CT administration

Conclusions Torino, Italy Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Conclusions Torino, Italy

We observed a signal of an improved survival in LCNC patients Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery We observed a signal of an improved survival in LCNC patients treated with adjuvant CT We did not identify a particular subset of patients in which adjuvant CT might be more appropriate Prospective data collection (ESTS prospective database), will hopefully help to define more tailored treatment strategy for such aggressive neoplasm

Thank you very much for your attention Torino, Italy Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Thank you very much for your attention Torino, Italy

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery

Cause of death Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Cause of death

Local recurrences: 61 Distant MTS: 140 (26 in the adjuvant CT group) Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Local recurrences: 61 (26 in the adjuvant CT group) Distant MTS: 140 (59 in the adjuvant CT group)

Stage I OS 3-y surv rate: 63 % 5-y surv rate: 51 % Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Stage I OS 3-y surv rate: 63 % 5-y surv rate: 51 %

Statistical analysis Kaplan-Meier method: probabilities of survival Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Statistical analysis Kaplan-Meier method: probabilities of survival Cox proportional hazards regression model with shared frailty: effect of adjuvant CT on OS Effect modifications by subgroups: inclusion in the model an interaction term between the covariate indicating adjuvant CT and the subgroup covariate of interest, adjusting for the others

NET morphological/immunohistochemical Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery NET morphological/immunohistochemical characteristics: Neuroendocrine morphology (organoid nesting, palisading rosettes and trabeculae High mitotic rate (11 or more) Abundant necrosis Large cell size Low nuclear/citoplasm ratio Tumor cells positive for neuroendocrine markers: Synaptophysisn Chromogranin A CD56 Chromogranin A Synaptophysisn

Study limitations: retrospective and multicenter design Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Study limitations: retrospective and multicenter design long recruitment period possible inherent treatment selection bias (pts receiving CT may have been selected among those with better clinical/functional conditions)

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Future directions: Future clinical trials might be "ad hoc"designed and new (biological) drugs might be tested to treat such aggressive neoplasms

LCNC: Due to its rarity and the lack of RCT, LCNC’s optimal treatment Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery LCNC: Due to its rarity and the lack of RCT, LCNC’s optimal treatment is still debated Few clinical papers evaluated the role of induction/adjuvant CT

Recent increased incidence: 2.3 – 2.8 cases/100,000/year Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery Recent increased incidence: 2.3 – 2.8 cases/100,000/year (diagnostic techniques improvement; lung cancer screening programs diffusion) Yao JC: J Clin Oncol. 2008 Jun 20;26:3063-72